Related Experiment Videos
Beta-adrenergic blocking drugs in severe heart failure
1Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California, USA.
Reviews in Cardiovascular Medicine
|November 26, 2002
Summary
Carvedilol, a beta-blocker, significantly reduces mortality and hospitalizations in advanced heart failure patients. This drug offers survival benefits, even for high-risk individuals, supporting its use in severe chronic heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Beta-adrenergic blocking drugs improve outcomes in mild to moderate heart failure.
- The role of sympathetic nervous system activation in advanced heart failure is complex, with mixed results from previous antiadrenergic therapies.
Purpose of the Study:
- To evaluate the efficacy of carvedilol, a combined nonselective beta-adrenergic and alpha-adrenergic receptor blocker, in patients with advanced heart failure.
Main Methods:
- The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial enrolled patients with advanced heart failure.
- Participants received carvedilol in addition to standard therapy, including angiotensin-converting enzyme inhibitors.
Main Results:
- Carvedilol significantly reduced all-cause mortality by 35% (from 18.5% to 11.4% annually).
- All-cause hospitalizations decreased by 20%, and heart failure-specific hospitalizations by 33%.
- Benefits were observed across all subgroups, including those at highest risk.
Conclusions:
- Carvedilol demonstrates a significant salutary effect on the natural history of advanced heart failure.
- The findings support the routine use of carvedilol in patients with advanced chronic heart failure, alongside ACE inhibitors.